Oscar R Benavente Selected Research

Secondary Prevention

12/2021	Is Blood Pressure Lowering in the Very Elderly With Previous Stroke Associated With a Higher Risk of Adverse Events?
1/2020	Functional health and white matter hyperintensities as effect modifiers of blood pressure-lowering on cognitive function and vascular events in older Secondary Prevention of Small Subcortical Strokes trial participants.
8/2019	Effect of Postural Hypotension on Recurrent Stroke: Secondary Prevention of Small Subcortical Strokes (SPS3) Study.
1/2019	Cerebral White Matter Hyperintensities, Kidney Function Decline, and Recurrent Stroke After Intensive Blood Pressure Lowering: Results From the Secondary Prevention of Small Subcortical Strokes ( SPS 3) Trial.
1/2019	Genome-wide association analysis of common genetic variants of resistant hypertension.
8/2017	Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions.
7/2017	Post Hoc Analyses of Randomized Clinical Trial for the Effect of Clopidogrel Added to Aspirin on Kidney Function.
1/2017	Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes).
3/2016	Inflammatory Markers and Outcomes After Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study.
1/2016	Morphological classification of penetrating artery pontine infarcts and association with risk factors and prognosis: The SPS3 trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Oscar R Benavente Research Topics

Disease

54	Stroke (Strokes) 12/2021 - 06/2002
24	Lacunar Stroke 08/2019 - 01/2011
14	Ischemic Stroke 01/2021 - 08/2012
7	Hemorrhage 01/2019 - 08/2012
6	Hypertension (High Blood Pressure) 01/2021 - 01/2017
5	Myocardial Infarction 01/2021 - 08/2012
4	Diabetes Mellitus 01/2021 - 09/2014
4	Infarction (Infarctions) 01/2020 - 09/2014
4	Cognitive Dysfunction 06/2015 - 02/2007
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 01/2019
3	Transient Ischemic Attack 01/2020 - 02/2011
2	Atrial Fibrillation 02/2022 - 01/2021
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 03/2014
2	Cerebral Hemorrhage 01/2019 - 07/2013
2	Vascular Diseases (Vascular Disease) 07/2015 - 08/2012
1	Syncope (Fainting) 12/2021
1	Brain Injuries (Brain Injury) 01/2021
1	Orthostatic Hypotension (Postural Hypotension) 08/2019
1	Cerebral Small Vessel Diseases 01/2019
1	Pathologic Constriction (Stenosis) 06/2018
1	Embolic Stroke 06/2018
1	Intracranial Embolism 06/2018
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2018
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2018
1	Neoplasms (Cancer) 01/2018
1	Ischemia 01/2018
1	Disease Progression 07/2017
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2015
1	Brain Ischemia (Cerebral Ischemia) 07/2015
1	Pathologic Dilatation (Ectasia) 05/2015
1	Isolated Systolic Hypertension 10/2014
1	Myocardial Ischemia (Ischemic Heart Diseases) 10/2014

Drug/Important Bio-Agent (IBA)

15	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020 - 02/2011
12	Clopidogrel (Plavix)FDA Link 01/2018 - 02/2011
3	AnticoagulantsIBA 02/2022 - 06/2018
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2019 - 02/2011
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
2	C-Reactive ProteinIBA 01/2020 - 03/2014
2	Phosphodiesterase InhibitorsIBA 01/2019 - 01/2019
2	Cilostazol (Pletal)FDA LinkGeneric 01/2019 - 04/2015
2	Biomarkers (Surrogate Marker)IBA 03/2016 - 03/2014
2	Dipyridamole (Persantine)FDA LinkGeneric 04/2015 - 02/2011
1	GenieIBA 01/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021
1	Antihypertensive Agents (Antihypertensives)IBA 01/2021
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2021
1	DiureticsIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	ThiazidesIBA 01/2021
1	LipidsIBA 01/2020
1	Dabigatran FDA Link 01/2020
1	hydroxide ionIBA 08/2019
1	CholesterolIBA 01/2019
1	trandolapril (Mavik)FDA LinkGeneric 01/2019
1	Verapamil (Calan)FDA LinkGeneric 01/2019
1	Factor Xa InhibitorsIBA 06/2018
1	RivaroxabanIBA 06/2018
1	omega-Chloroacetophenone (Mace)IBA 01/2017
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2017
1	Illicit Drugs (Recreational Drugs)IBA 04/2016
1	Cocaine (Cocaine HCl)IBA 04/2016
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 03/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2016
1	Interleukin-6 (Interleukin 6)IBA 03/2016
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 03/2016
1	Serum Amyloid A Protein (Serum Amyloid A)IBA 03/2016
1	CD40 Ligand (CD40L)IBA 03/2016
1	Cytochrome P-450 CYP2C19IBA 05/2015
1	Hemoglobins (Hemoglobin)IBA 10/2014

Therapy/Procedure

38	Secondary Prevention 12/2021 - 02/2007
14	Therapeutics 01/2019 - 01/2011
1	Percutaneous Coronary Intervention 05/2015
1	Activities of Daily Living (ADL) 03/2015
1	DDP-BLM protocol 08/2014
1	Thrombolytic Therapy 07/2013
1	Endarterectomy (Thromboendarterectomy) 06/2002